Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIRATE: RRx-001 + Chemo in Pediatric Tumors
NCT04525014Phase 1Terminated
- Sponsor
- EpicentRx
- Start
- Jan 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Nibrozetone in malignant solid tumor and central nervous system tumor, sponsored by EpicentRx. Primary endpoint: Recommended Phase 2 Dose at 18 months. Started Jan 2023; status: terminated.
02
Drugs
Nibrozetone
03
Conditions
malignant solid tumorcentral nervous system tumor
Beyond the preview
Go deeper on NCT04525014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04525014.